BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 2019;176:1455-69. [PMID: 29981240 DOI: 10.1111/bph.14440] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 26.3] [Reference Citation Analysis]
Number Citing Articles
1 Chesney E, McGuire P, Freeman TP, Strang J, Englund A. Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products. Ther Adv Psychopharmacol 2020;10:2045125320954992. [PMID: 32973998 DOI: 10.1177/2045125320954992] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chen S, Wang Y, Wang X, He M, Zhang L, Dong Z. PKA-Dependent Membrane Surface Recruitment of CI-AMPARs Is Crucial for BCP-Mediated Protection Against Post-acute Ischemic Stroke Cognitive Impairment. Front Neurol 2020;11:566067. [PMID: 33391143 DOI: 10.3389/fneur.2020.566067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Shen B, Zhang D, Zeng X, Guan L, Yang G, Liu L, Huang J, Li Y, Hong S, Li L. Cannabidiol inhibits methamphetamine-induced dopamine release via modulation of the DRD1-MeCP2-BDNF-TrkB signaling pathway. Psychopharmacology (Berl) 2022. [PMID: 34997862 DOI: 10.1007/s00213-021-06051-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Fearby N, Penman S, Thanos P. Effects of Δ9-Tetrahydrocannibinol (THC) on Obesity at Different Stages of Life: A Literature Review. Int J Environ Res Public Health 2022;19:3174. [PMID: 35328862 DOI: 10.3390/ijerph19063174] [Reference Citation Analysis]
5 Prieto JP, López Hill X, Urbanavicius J, Sanchez V, Nadal X, Scorza C. Cannabidiol Prevents the Expression of the Locomotor Sensitization and the Metabolic Changes in the Nucleus Accumbens and Prefrontal Cortex Elicited by the Combined Administration of Cocaine and Caffeine in Rats. Neurotox Res 2020;38:478-86. [PMID: 32415526 DOI: 10.1007/s12640-020-00218-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Bi GH, Galaj E, He Y, Xi ZX. Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents. Addict Biol 2020;25:e12783. [PMID: 31215752 DOI: 10.1111/adb.12783] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
7 Kowalski CW, Ragozzino FJ, Lindberg JEM, Peterson B, Lugo JM, McLaughlin RJ, Peters JH. Cannabidiol activation of vagal afferent neurons requires TRPA1. J Neurophysiol 2020;124:1388-98. [PMID: 32965166 DOI: 10.1152/jn.00128.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Mazeh AC, Angus JA, Wright CE. Pharmacological characterisation of the CB1 receptor antagonist activity of cannabidiol in the rat vas deferens bioassay. Eur J Pharmacol 2021;909:174433. [PMID: 34416240 DOI: 10.1016/j.ejphar.2021.174433] [Reference Citation Analysis]
9 Martin EL, Strickland JC, Schlienz NJ, Munson J, Jackson H, Bonn-Miller MO, Vandrey R. Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. Front Psychiatry 2021;12:729800. [PMID: 34566726 DOI: 10.3389/fpsyt.2021.729800] [Reference Citation Analysis]
10 Romigi A, Bari M, Liguori C, Izzi F, Rapino C, Nuccetelli M, Battista N, Bernardini S, Centonze D, Mercuri NB, Placidi F, Maccarrone M. CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study. CNS Neurol Disord Drug Targets 2020;19:142-7. [PMID: 32148204 DOI: 10.2174/1871527319666200309115602] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ferrisi R, Ceni C, Bertini S, Macchia M, Manera C, Gado F. Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB2R modulators in neurodegenerative diseases. Pharmacol Res 2021;170:105607. [PMID: 34089867 DOI: 10.1016/j.phrs.2021.105607] [Reference Citation Analysis]
12 Feng Z, Liang T, Wang S, Chen M, Hou T, Zhao J, Chen H, Zhou Y, Xie XQ. Binding Characterization of GPCRs-Modulator by Molecular Complex Characterizing System (MCCS). ACS Chem Neurosci 2020;11:3333-45. [PMID: 32941011 DOI: 10.1021/acschemneuro.0c00457] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Petrie GN, Nastase AS, Aukema RJ, Hill MN. Endocannabinoids, cannabinoids and the regulation of anxiety. Neuropharmacology 2021;195:108626. [PMID: 34116110 DOI: 10.1016/j.neuropharm.2021.108626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Luján MÁ, Valverde O. The Pro-neurogenic Effects of Cannabidiol and Its Potential Therapeutic Implications in Psychiatric Disorders. Front Behav Neurosci 2020;14:109. [PMID: 32676014 DOI: 10.3389/fnbeh.2020.00109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mlost J, Kędziora M, Starowicz K. Computational Approach Reveals Pronociceptive Potential of Cannabidiol in Osteoarthritis: Role of Transient Receptor Potential Channels. Pharmaceuticals (Basel) 2021;14:964. [PMID: 34681188 DOI: 10.3390/ph14100964] [Reference Citation Analysis]
16 Pandelides Z, Aluru N, Thornton C, Watts HE, Willett KL. Transcriptomic Changes and the Roles of Cannabinoid Receptors and PPARγ in Developmental Toxicities Following Exposure to Δ9-Tetrahydrocannabinol and Cannabidiol. Toxicol Sci 2021;182:44-59. [PMID: 33892503 DOI: 10.1093/toxsci/kfab046] [Reference Citation Analysis]
17 Wang F, Li M, Lin C, Jin S, Li H, Lu Y, Wang H, Wang H, Wang X. Cannabidiol-dihydroartemisinin conjugates for ameliorating neuroinflammation with reduced cytotoxicity. Bioorg Med Chem 2021;39:116131. [PMID: 33852975 DOI: 10.1016/j.bmc.2021.116131] [Reference Citation Analysis]
18 Martín-Sánchez A, González-Pardo H, Alegre-Zurano L, Castro-Zavala A, López-Taboada I, Valverde O, Conejo NM. Early-life stress induces emotional and molecular alterations in female mice that are partially reversed by cannabidiol. Prog Neuropsychopharmacol Biol Psychiatry 2021;115:110508. [PMID: 34973413 DOI: 10.1016/j.pnpbp.2021.110508] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Morales P, Muller C, Jagerovic N, Reggio PH. Targeting CB2 and TRPV1: Computational Approaches for the Identification of Dual Modulators. Front Mol Biosci 2022;9:841190. [DOI: 10.3389/fmolb.2022.841190] [Reference Citation Analysis]
20 Lim KJH, Lim YP, Hartono YD, Go MK, Fan H, Yew WS. Biosynthesis of Nature-Inspired Unnatural Cannabinoids. Molecules 2021;26:2914. [PMID: 34068935 DOI: 10.3390/molecules26102914] [Reference Citation Analysis]
21 Lu L, Williams G, Doherty P. 2-Linoleoylglycerol Is a Partial Agonist of the Human Cannabinoid Type 1 Receptor that Can Suppress 2-Arachidonolyglycerol and Anandamide Activity. Cannabis Cannabinoid Res 2019;4:231-9. [PMID: 31872059 DOI: 10.1089/can.2019.0030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Murillo-Rodríguez E, Budde H, Veras AB, Rocha NB, Telles-Correia D, Monteiro D, Cid L, Yamamoto T, Machado S, Torterolo P. The Endocannabinoid System May Modulate Sleep Disorders in Aging. Curr Neuropharmacol 2020;18:97-108. [PMID: 31368874 DOI: 10.2174/1570159X17666190801155922] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Cheung KAK, Peiris H, Wallace G, Holland OJ, Mitchell MD. The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids. Int J Mol Sci 2019;20:E6079. [PMID: 31810321 DOI: 10.3390/ijms20236079] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
24 Chye Y, Christensen E, Solowij N, Yücel M. The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder. Front Psychiatry 2019;10:63. [PMID: 30837904 DOI: 10.3389/fpsyt.2019.00063] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
25 Barnard IL, Onofrychuk TJ, Sandini TM, Mcelroy DL, Zagzoog A, Roebuck AJ, Austin-scott FV, Laprairie RB, Howland JG. The effects of acute Cannabis smoke or Δ9-THC injections on the trial-unique, nonmatching-to- location and five-choice serial reaction time tasks in male Long-Evans rats. Neurobiology of Learning and Memory 2022. [DOI: 10.1016/j.nlm.2022.107624] [Reference Citation Analysis]
26 Meah F, Lundholm M, Emanuele N, Amjed H, Poku C, Agrawal L, Emanuele MA. The effects of cannabis and cannabinoids on the endocrine system. Rev Endocr Metab Disord 2021. [PMID: 34460075 DOI: 10.1007/s11154-021-09682-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Kim HJJ, Zagzoog A, Black T, Baccetto SL, Ezeaka UC, Laprairie RB. Impact of the mouse estrus cycle on cannabinoid receptor agonist-induced molecular and behavioral outcomes. Pharmacol Res Perspect 2022;10:e00950. [PMID: 35466560 DOI: 10.1002/prp2.950] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Kwan Cheung KA, Mitchell MD, Heussler HS. Cannabidiol and Neurodevelopmental Disorders in Children. Front Psychiatry 2021;12:643442. [PMID: 34093265 DOI: 10.3389/fpsyt.2021.643442] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Martin EL, Doncheck EM, Reichel CM, McRae-Clark AL. Consideration of sex as a biological variable in the translation of pharmacotherapy for stress-associated drug seeking. Neurobiol Stress 2021;15:100364. [PMID: 34345636 DOI: 10.1016/j.ynstr.2021.100364] [Reference Citation Analysis]
30 Morales P, Reggio PH. CBD: A New Hope? ACS Med Chem Lett 2019;10:694-5. [PMID: 31097982 DOI: 10.1021/acsmedchemlett.9b00127] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
31 Breijyeh Z, Jubeh B, Bufo SA, Karaman R, Scrano L. Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses. Toxins (Basel) 2021;13:117. [PMID: 33562446 DOI: 10.3390/toxins13020117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
32 Holloman BL, Nagarkatti M, Nagarkatti P. Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases. Int J Mol Sci 2021;22:7302. [PMID: 34298921 DOI: 10.3390/ijms22147302] [Reference Citation Analysis]
33 Martin LJ, Banister SD, Bowen MT. Understanding the complex pharmacology of cannabidiol: Mounting evidence suggests a common binding site with cholesterol. Pharmacol Res 2021;166:105508. [PMID: 33610721 DOI: 10.1016/j.phrs.2021.105508] [Reference Citation Analysis]
34 Luján MÁ, Cheer JF, Melis M. Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement. Curr Opin Pharmacol 2021;56:29-38. [PMID: 33068883 DOI: 10.1016/j.coph.2020.08.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Galaj E, Xi ZX. Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals. Int J Mol Sci 2020;22:E134. [PMID: 33374481 DOI: 10.3390/ijms22010134] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Solowij N, Broyd S, Greenwood LM, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci 2019;269:17-35. [PMID: 30661105 DOI: 10.1007/s00406-019-00978-2] [Cited by in Crossref: 97] [Cited by in F6Publishing: 78] [Article Influence: 32.3] [Reference Citation Analysis]
37 De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, Maurage P, Cottencin O, Carrieri PM, Rolland B. Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain. Front Pharmacol 2019;10:627. [PMID: 31214036 DOI: 10.3389/fphar.2019.00627] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
38 Calpe-lópez C, Gasparyan A, Navarrete F, Manzanares J, Miñarro J, Aguilar MA. Cannabidiol prevents priming- and stress-induced reinstatement of the conditioned place preference induced by cocaine in mice. J Psychopharmacol 2021;35:864-74. [DOI: 10.1177/0269881120965952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
39 Kirkland AE, Fadus MC, Gruber SA, Gray KM, Wilens TE, Squeglia LM. A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Res 2021;308:114347. [PMID: 34952255 DOI: 10.1016/j.psychres.2021.114347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
40 Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Front Neurol 2018;9:759. [PMID: 30258398 DOI: 10.3389/fneur.2018.00759] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 14.0] [Reference Citation Analysis]
41 Vigil JM, Montera MA, Pentkowski NS, Diviant JP, Orozco J, Ortiz AL, Rael LJ, Westlund KN. The Therapeutic Effectiveness of Full Spectrum Hemp Oil Using a Chronic Neuropathic Pain Model. Life (Basel) 2020;10:E69. [PMID: 32443500 DOI: 10.3390/life10050069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Galaj E, Xi ZX. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. CNS Drugs 2019;33:1001-30. [PMID: 31549358 DOI: 10.1007/s40263-019-00664-w] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
43 Thompson KJ, Tobin AB. Crosstalk between the M1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease? Cell Signal 2020;70:109545. [PMID: 31978506 DOI: 10.1016/j.cellsig.2020.109545] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
44 Narouze S, Strand N, Roychoudhury P. Cannabinoids-based Medicine Pharmacology, Drug Interactions, and Perioperative Management of Surgical Patients. Adv Anesth 2020;38:167-88. [PMID: 34106833 DOI: 10.1016/j.aan.2020.08.004] [Reference Citation Analysis]
45 Alexander SPH, Molina-Holgado F. Cannabinoids and their actions: An update. Br J Pharmacol 2019;176:1359-60. [PMID: 31032895 DOI: 10.1111/bph.14627] [Reference Citation Analysis]
46 Aderibigbe AO, Pandey P, Doerksen RJ. Negative allosteric modulators of cannabinoid receptor 1: Ternary complexes including CB1, orthosteric CP55940 and allosteric ORG27569. J Biomol Struct Dyn 2021;:1-19. [PMID: 33480332 DOI: 10.1080/07391102.2021.1873187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ghovanloo MR, Choudhury K, Bandaru TS, Fouda MA, Rayani K, Rusinova R, Phaterpekar T, Nelkenbrecher K, Watkins AR, Poburko D, Thewalt J, Andersen OS, Delemotte L, Goodchild SJ, Ruben PC. Cannabidiol inhibits the skeletal muscle Nav1.4 by blocking its pore and by altering membrane elasticity. J Gen Physiol 2021;153:e202012701. [PMID: 33836525 DOI: 10.1085/jgp.202012701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Sermet S, Li J, Bach A, Crawford RB, Kaminski NE. Cannabidiol selectively modulates interleukin (IL)-1β and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology 2021;464:153016. [PMID: 34740670 DOI: 10.1016/j.tox.2021.153016] [Reference Citation Analysis]
49 Hamilton AJ, Payne AD, Mocerino M, Gunosewoyo H. Imaging Cannabinoid Receptors: A Brief Collection of Covalent and Fluorescent Probes for CB1 and CB2 Receptors. Aust J Chem 2021;74:416. [DOI: 10.1071/ch21007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Sugaya Y, Kano M. Endocannabinoid-Mediated Control of Neural Circuit Excitability and Epileptic Seizures. Front Neural Circuits 2022;15:781113. [DOI: 10.3389/fncir.2021.781113] [Reference Citation Analysis]
51 Frajerman A, Scoriels L, Kebir O, Chaumette B. Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment? Int J Mol Sci 2021;22:6881. [PMID: 34206945 DOI: 10.3390/ijms22136881] [Reference Citation Analysis]
52 Hashiesh HM, Sharma C, Goyal SN, Jha NK, Ojha S. Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist. Front Pharmacol 2021;12:702675. [PMID: 34393784 DOI: 10.3389/fphar.2021.702675] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Etemad L, Karimi G, Alavi MS, Roohbakhsh A. Pharmacological effects of cannabidiol by transient receptor potential channels. Life Sci 2022;:120582. [PMID: 35483477 DOI: 10.1016/j.lfs.2022.120582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
54 Falasca V, Falasca M. Targeting the Endocannabinoidome in Pancreatic Cancer. Biomolecules 2022;12:320. [DOI: 10.3390/biom12020320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Williams CM, Stephens GJ. Development of cannabidiol as a treatment for severe childhood epilepsies. Br J Pharmacol 2020;177:5509-17. [PMID: 32986848 DOI: 10.1111/bph.15274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Abate G, Uberti D, Tambaro S. Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy. Biology (Basel) 2021;10:542. [PMID: 34204237 DOI: 10.3390/biology10060542] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Baranowska-Kuczko M, Kozłowska H, Kloza M, Sadowska O, Kozłowski M, Kusaczuk M, Kasacka I, Malinowska B. Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities. J Hypertens 2020;38:896-911. [PMID: 31800399 DOI: 10.1097/HJH.0000000000002333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
58 Metz VG, da Rosa JLO, Rossato DR, Milanesi LH, Burger ME, Pase CS. Cannabidiol prevents amphetamine relapse and modulates D1- and D2-receptor levels in mesocorticolimbic brain areas of rats. Eur Neuropsychopharmacol 2021;50:23-33. [PMID: 33951588 DOI: 10.1016/j.euroneuro.2021.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Finn DP, Haroutounian S, Hohmann AG, Krane E, Soliman N, Rice ASC. Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. Pain 2021;162:S5-S25. [PMID: 33729211 DOI: 10.1097/j.pain.0000000000002268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
60 Navarrete F, Gasparyan A, Manzanares J. CBD-mediated regulation of heroin withdrawal-induced behavioural and molecular changes in mice. Addict Biol 2022;27:e13150. [PMID: 35229949 DOI: 10.1111/adb.13150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Vitale RM, Iannotti FA, Schiano Moriello A, Tunisi L, Piscitelli F, Savopoulos R, Cristino L, De Petrocellis L, Amodeo P, Gray R, Di Marzo V. Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation. Biomolecules 2021;11:1134. [PMID: 34439801 DOI: 10.3390/biom11081134] [Reference Citation Analysis]
62 Boehnke KF, Häuser W, Fitzcharles MA. Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain). Curr Rheumatol Rep 2022. [PMID: 35503198 DOI: 10.1007/s11926-022-01077-3] [Reference Citation Analysis]
63 Navarrete F, García-Gutiérrez MS, Gasparyan A, Austrich-Olivares A, Manzanares J. Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders. Front Pharmacol 2021;12:626010. [PMID: 34093179 DOI: 10.3389/fphar.2021.626010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol Adverse Effects and Toxicity. Curr Neuropharmacol 2019;17:974-89. [PMID: 31161980 DOI: 10.2174/1570159X17666190603171901] [Cited by in Crossref: 84] [Cited by in F6Publishing: 35] [Article Influence: 42.0] [Reference Citation Analysis]
65 Carmona-Hidalgo B, García-Martín A, Muñoz E, González-Mariscal I. Detrimental Effect of Cannabidiol on the Early Onset of Diabetic Nephropathy in Male Mice. Pharmaceuticals (Basel) 2021;14:863. [PMID: 34577563 DOI: 10.3390/ph14090863] [Reference Citation Analysis]
66 Kopustinskiene DM, Masteikova R, Lazauskas R, Bernatoniene J. Cannabis sativa L. Bioactive Compounds and Their Protective Role in Oxidative Stress and Inflammation. Antioxidants 2022;11:660. [DOI: 10.3390/antiox11040660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Ghovanloo MR, Ruben PC. Cannabidiol and Sodium Channel Pharmacology: General Overview, Mechanism, and Clinical Implications. Neuroscientist 2021;:10738584211017009. [PMID: 34027742 DOI: 10.1177/10738584211017009] [Reference Citation Analysis]
68 Lee H, Tamia G, Song H, Amarakoon D, Wei C, Lee S. Cannabidiol exerts anti-proliferative activity via a cannabinoid receptor 2-dependent mechanism in human colorectal cancer cells. International Immunopharmacology 2022;108:108865. [DOI: 10.1016/j.intimp.2022.108865] [Reference Citation Analysis]
69 Nouri K, Anooshe M, Karimi-Haghighi S, Mousavi Z, Haghparast A. Involvement of Hippocampal D1-Like Dopamine Receptors in the Inhibitory Effect of Cannabidiol on Acquisition and Expression of Methamphetamine-Induced Conditioned Place Preference. Neurochem Res 2021;46:2008-18. [PMID: 33993443 DOI: 10.1007/s11064-021-03350-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Borgan F, Kokkinou M, Howes O. The Cannabinoid CB1 Receptor in Schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging 2021;6:646-59. [PMID: 33077399 DOI: 10.1016/j.bpsc.2020.06.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
71 Gasparyan A, Navarrete F, Manzanares J. Cannabidiol and Sertraline Regulate Behavioral and Brain Gene Expression Alterations in an Animal Model of PTSD. Front Pharmacol 2021;12:694510. [PMID: 34262461 DOI: 10.3389/fphar.2021.694510] [Reference Citation Analysis]
72 Aviz-Amador A, Contreras-Puentes N, Mercado-Camargo J. Virtual screening using docking and molecular dynamics of cannabinoid analogs against CB1 and CB2 receptors. Comput Biol Chem 2021;95:107590. [PMID: 34700256 DOI: 10.1016/j.compbiolchem.2021.107590] [Reference Citation Analysis]
73 Shahbazi F, Grandi V, Banerjee A, Trant JF. Cannabinoids and Cannabinoid Receptors: The Story so Far. iScience 2020;23:101301. [PMID: 32629422 DOI: 10.1016/j.isci.2020.101301] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
74 Lewis-Bakker MM, Yang Y, Vyawahare R, Kotra LP. Extractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses. Cannabis Cannabinoid Res 2019;4:183-94. [PMID: 31559334 DOI: 10.1089/can.2018.0067] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
75 Burggren AC, Shirazi A, Ginder N, London ED. Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives. Am J Drug Alcohol Abuse 2019;45:563-79. [PMID: 31365275 DOI: 10.1080/00952990.2019.1634086] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
76 Morales P, Jagerovic N. Novel approaches and current challenges with targeting the endocannabinoid system. Expert Opin Drug Discov 2020;15:917-30. [PMID: 32336154 DOI: 10.1080/17460441.2020.1752178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
77 Clayton P, Subah S, Venkatesh R, Hill M, Bogoda N. Palmitoylethanolamide: A Potential Alternative to Cannabidiol. J Diet Suppl 2021;:1-26. [PMID: 34842030 DOI: 10.1080/19390211.2021.2005733] [Reference Citation Analysis]
78 Fischer AS, Tapert SF, Lee Louie D, Schatzberg AF, Singh MK. Cannabis and the Developing Adolescent Brain. Curr Treat Options Psychiatry 2020;7:144-61. [PMID: 32714742 DOI: 10.1007/s40501-020-00202-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Alenabi A, Malekinejad H. Cannabinoids pharmacological effects are beyond the palliative effects: CB2 cannabinoid receptor agonist induced cytotoxicity and apoptosis in human colorectal cancer cells (HT-29). Mol Cell Biochem 2021;476:3285-301. [PMID: 33886060 DOI: 10.1007/s11010-021-04158-6] [Reference Citation Analysis]
80 Greenwood LM, Broyd SJ, van Hell HH, Todd J, Jones A, Murray RM, Croft RJ, Michie PT, Solowij N. Acute effects of Δ9-tetrahydrocannabinol and cannabidiol on auditory mismatch negativity. Psychopharmacology (Berl) 2021. [PMID: 34719731 DOI: 10.1007/s00213-021-05997-3] [Reference Citation Analysis]
81 Saldaña-Shumaker SL, Grenning AJ, Cunningham CW. Modern approaches to the development of synthetic cannabinoid receptor probes. Pharmacol Biochem Behav 2021;203:173119. [PMID: 33508249 DOI: 10.1016/j.pbb.2021.173119] [Reference Citation Analysis]
82 Nichols JM, Kaplan BLF. Immune Responses Regulated by Cannabidiol. Cannabis Cannabinoid Res 2020;5:12-31. [PMID: 32322673 DOI: 10.1089/can.2018.0073] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 26.5] [Reference Citation Analysis]
83 Chye Y, Kirkham R, Lorenzetti V, McTavish E, Solowij N, Yücel M. Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence. Biol Psychiatry Cogn Neurosci Neuroimaging 2021;6:627-35. [PMID: 32948510 DOI: 10.1016/j.bpsc.2020.07.009] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Silva-Cardoso GK, Lazarini-Lopes W, Hallak JE, Crippa JA, Zuardi AW, Garcia-Cairasco N, Leite-Panissi CRA. Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: Possible role of CB1 and TRPV1 receptors. Neuropharmacology 2021;197:108712. [PMID: 34274349 DOI: 10.1016/j.neuropharm.2021.108712] [Reference Citation Analysis]
85 Martin EL, McRae-Clark AL. Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder. Curr Addict Rep 2020;7:545-52. [PMID: 33816054 DOI: 10.1007/s40429-020-00342-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Suraev A, Grunstein RR, Marshall NS, D'Rozario AL, Gordon CJ, Bartlett DJ, Wong K, Yee BJ, Vandrey R, Irwin C, Arnold JC, McGregor IS, Hoyos CM. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for chronic insomnia disorder ('CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ Open 2020;10:e034421. [PMID: 32430450 DOI: 10.1136/bmjopen-2019-034421] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
87 Galaj E, Bi GH, Yang HJ, Xi ZX. Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms. Neuropharmacology 2020;167:107740. [PMID: 31437433 DOI: 10.1016/j.neuropharm.2019.107740] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 12.3] [Reference Citation Analysis]
88 Mlost J, Bryk M, Starowicz K. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. Int J Mol Sci 2020;21:E8870. [PMID: 33238607 DOI: 10.3390/ijms21228870] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
89 Gado F, Meini S, Bertini S, Digiacomo M, Macchia M, Manera C. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery. Future Med Chem 2019;11:2019-37. [PMID: 31517528 DOI: 10.4155/fmc-2019-0005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
90 Steardo L Jr, Carbone EA, Menculini G, Moretti P, Steardo L, Tortorella A. Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Review. Life (Basel) 2021;11:214. [PMID: 33803374 DOI: 10.3390/life11030214] [Reference Citation Analysis]
91 Greco R, Demartini C, Zanaboni AM, Francavilla M, De Icco R, Ahmad L, Tassorelli C. The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. Headache 2022;62:227-40. [PMID: 35179780 DOI: 10.1111/head.14267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Ji X, Zeng Y, Wu J. The CB2 Receptor as a Novel Therapeutic Target for Epilepsy Treatment. Int J Mol Sci 2021;22:8961. [PMID: 34445666 DOI: 10.3390/ijms22168961] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
93 Osborne AL, Solowij N, Babic I, Lum JS, Newell KA, Huang XF, Weston-Green K. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2019;95:109666. [PMID: 31202911 DOI: 10.1016/j.pnpbp.2019.109666] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
94 Pandey P, Roy KK, Doerksen RJ. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist. J Biomol Struct Dyn 2020;38:32-47. [PMID: 30652534 DOI: 10.1080/07391102.2019.1567384] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
95 Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants (Basel) 2019;9:E21. [PMID: 31881765 DOI: 10.3390/antiox9010021] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 31.0] [Reference Citation Analysis]
96 Cochrane-Snyman KC, Cruz C, Morales J, Coles M. The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men. Med Sci Sports Exerc 2021;53:1460-72. [PMID: 33481484 DOI: 10.1249/MSS.0000000000002606] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
97 Joshi N, Onaivi ES. Psychiatric Disorders and Cannabinoid Receptors. Adv Exp Med Biol 2021;1264:131-53. [PMID: 33332008 DOI: 10.1007/978-3-030-57369-0_9] [Reference Citation Analysis]
98 Wiese B, Wilson-Poe AR. Emerging Evidence for Cannabis' Role in Opioid Use Disorder. Cannabis Cannabinoid Res 2018;3:179-89. [PMID: 30221197 DOI: 10.1089/can.2018.0022] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 12.5] [Reference Citation Analysis]
99 Mielnik CA, Lam VM, Ross RA. CB1 allosteric modulators and their therapeutic potential in CNS disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2021;106:110163. [DOI: 10.1016/j.pnpbp.2020.110163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
100 Wang Y, Yu Z, Xiao W, Lu S, Zhang J. Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery. Drug Discov Today 2021;26:690-703. [PMID: 33301977 DOI: 10.1016/j.drudis.2020.12.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
101 McKee SA, McRae-Clark AL. Consideration of sex and gender differences in addiction medication response. Biol Sex Differ 2022;13:34. [PMID: 35761351 DOI: 10.1186/s13293-022-00441-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Ramírez-Orozco RE, García-Ruiz R, Morales P, Villalón CM, Villafán-Bernal JR, Marichal-Cancino BA. Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. Curr Neuropharmacol 2019;17:947-60. [PMID: 31146657 DOI: 10.2174/1570159X17666190118143014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
103 Luján MÁ, Alegre-Zurano L, Martín-Sánchez A, Cantacorps L, Valverde O. CB1 receptor antagonist AM4113 reverts the effects of cannabidiol on cue and stress-induced reinstatement of cocaine-seeking behaviour in mice. Prog Neuropsychopharmacol Biol Psychiatry 2021;113:110462. [PMID: 34688811 DOI: 10.1016/j.pnpbp.2021.110462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Vitale RM, Iannotti FA, Amodeo P. The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets. Int J Mol Sci 2021;22:4876. [PMID: 34062987 DOI: 10.3390/ijms22094876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl) 2021;238:9-28. [PMID: 33221931 DOI: 10.1007/s00213-020-05712-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
106 Nagarkatti P, Miranda K, Nagarkatti M. Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019. Front Pharmacol 2020;11:589438. [PMID: 33240092 DOI: 10.3389/fphar.2020.589438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
107 Helcman M, Šmejkal K. Biological activity of Cannabis compounds: a modern approach to the therapy of multiple diseases. Phytochem Rev. [DOI: 10.1007/s11101-021-09777-x] [Reference Citation Analysis]
108 Zagzoog A, Mohamed KA, Kim HJJ, Kim ED, Frank CS, Black T, Jadhav PD, Holbrook LA, Laprairie RB. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10:20405. [PMID: 33230154 DOI: 10.1038/s41598-020-77175-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
109 McCartney D, Benson MJ, Desbrow B, Irwin C, Suraev A, McGregor IS. Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research. Sports Med Open 2020;6:27. [PMID: 32632671 DOI: 10.1186/s40798-020-00251-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
110 Laborde-Casterot H, Larabi IA, Dufayet L, Etting I, Alvarez JC, Vodovar D. Does cannabidiol induce cannabinoid hyperemesis syndrome? Clin Toxicol (Phila) 2020;58:1351-2. [PMID: 32163300 DOI: 10.1080/15563650.2020.1736298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
111 Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 2019;176:1455-69. [PMID: 29981240 DOI: 10.1111/bph.14440] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 26.3] [Reference Citation Analysis]
112 Breivogel CS, Wells JR, Jonas A, Mistry AH, Gravley ML, Patel RM, Whithorn BE, Brenseke BM. Comparison of the Neurotoxic and Seizure-Inducing Effects of Synthetic and Endogenous Cannabinoids with Δ9-Tetrahydrocannabinol. Cannabis Cannabinoid Res 2020;5:32-41. [PMID: 32322674 DOI: 10.1089/can.2019.0003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
113 Calpe-López C, García-Pardo MP, Aguilar MA. Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms. Molecules 2019;24:E2583. [PMID: 31315244 DOI: 10.3390/molecules24142583] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
114 Ledesma JC, Manzanedo C, Aguilar MA. Cannabidiol prevents several of the behavioral alterations related to cocaine addiction in mice. Prog Neuropsychopharmacol Biol Psychiatry 2021;111:110390. [PMID: 34157334 DOI: 10.1016/j.pnpbp.2021.110390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Szkudlarek HJ, Rodríguez-ruiz M, Hudson R, De Felice M, Jung T, Rushlow WJ, Laviolette SR. THC and CBD produce divergent effects on perception and panic behaviours via distinct cortical molecular pathways. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2021;104:110029. [DOI: 10.1016/j.pnpbp.2020.110029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
116 Franco V, Perucca E. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Drugs 2019;79:1435-54. [DOI: 10.1007/s40265-019-01171-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
117 Suraev AS, Marshall NS, Vandrey R, Mccartney D, Benson MJ, Mcgregor IS, Grunstein RR, Hoyos CM. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Medicine Reviews 2020;53:101339. [DOI: 10.1016/j.smrv.2020.101339] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
118 Moreno-sanz G, Ferreiro Vera C, Sánchez-carnerero C, Nadal Roura X, Sánchez de Medina Baena V. Biological Activity of Cannabis sativa L. Extracts Critically Depends on Solvent Polarity and Decarboxylation. Separations 2020;7:56. [DOI: 10.3390/separations7040056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 An D, Peigneur S, Hendrickx LA, Tytgat J. Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products. Int J Mol Sci 2020;21:E5064. [PMID: 32709050 DOI: 10.3390/ijms21145064] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
120 Patricio F, Morales-Andrade AA, Patricio-Martínez A, Limón ID. Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease. Front Pharmacol 2020;11:595635. [PMID: 33384602 DOI: 10.3389/fphar.2020.595635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
121 Laprairie RB, Mohamed KA, Zagzoog A, Kelly MEM, Stevenson LA, Pertwee R, Denovan-Wright EM, Thakur GA. Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling. Front Mol Neurosci 2019;12:257. [PMID: 31680861 DOI: 10.3389/fnmol.2019.00257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
122 Gendy MNS, Ibrahim C, Sloan ME, Le Foll B. Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade. Handb Exp Pharmacol 2020;258:395-420. [PMID: 31267165 DOI: 10.1007/164_2019_253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
123 Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Pina SD, Tambaro S, Memo M, Mastinu A. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sciences 2019;224:120-7. [DOI: 10.1016/j.lfs.2019.03.053] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 16.0] [Reference Citation Analysis]
124 Zhou J, Noori H, Burkovskiy I, Lafreniere JD, Kelly MEM, Lehmann C. Modulation of the Endocannabinoid System Following Central Nervous System Injury. Int J Mol Sci 2019;20:E388. [PMID: 30658442 DOI: 10.3390/ijms20020388] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
125 Fernández-Ruiz J, Galve-Roperh I, Sagredo O, Guzmán M. Possible therapeutic applications of cannabis in the neuropsychopharmacology field. Eur Neuropsychopharmacol 2020;36:217-34. [PMID: 32057592 DOI: 10.1016/j.euroneuro.2020.01.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
126 Schlag AK, Hindocha C, Zafar R, Nutt DJ, Curran HV. Cannabis based medicines and cannabis dependence: A critical review of issues and evidence. J Psychopharmacol 2021;35:773-85. [PMID: 33593117 DOI: 10.1177/0269881120986393] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Gelmi TJ, Weinmann W, Pfäffli M. Impact of smoking cannabidiol (CBD)-rich marijuana on driving ability. Forensic Sci Res 2021;6:195-207. [PMID: 34868711 DOI: 10.1080/20961790.2021.1946924] [Reference Citation Analysis]
128 Hernández-hernández E, García-fuster MJ. Dose-Dependent Antidepressant-Like Effects of Cannabidiol in Aged Rats. Front Pharmacol 2022;13:891842. [DOI: 10.3389/fphar.2022.891842] [Reference Citation Analysis]
129 Ferranti AS, Foster DJ. Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. Front Neurosci 2022;16:925792. [DOI: 10.3389/fnins.2022.925792] [Reference Citation Analysis]
130 Anooshe M, Nouri K, Karimi-Haghighi S, Mousavi Z, Haghparast A. Cannabidiol efficiently suppressed the acquisition and expression of methamphetamine-induced conditioned place preference in the rat. Behav Brain Res 2021;404:113158. [PMID: 33571569 DOI: 10.1016/j.bbr.2021.113158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
131 Gustafsson SB, Jacobsson SOP. Effects of cannabinoids on the development of chick embryos in ovo. Sci Rep 2019;9:13486. [PMID: 31530885 DOI: 10.1038/s41598-019-50004-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]